


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
LATEST RESEARCH RESULTS ON TQ-A3334 “TLR7 AGONIST” AND
BEPIROVIRSEN “ASO”
TO BE PRESENTED AT 2026 AASLD

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the results from a clinical study of TQ-A3334 (a TLR7 agonist), a national Category 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Group, have been selected as a “Late-Breaking Abstract” (LBA) at The Liver Meeting 2026 of the American Association for the Study of Liver Diseases (AASLD) and will be presented in the form of an oral presentation. Bepirovirsen (ASO), a product resulting from the strategic collaboration between CTTQ and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including one poster of distinction).

TQ-A3334 (TLR7 agonist)

An LBA:

Title of Abstract: Efficacy and Safety of an Oral TLR7 Agonist Through 48 Weeks in NAs-Treated Chronic HBV Infection: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial

Presenter: Professor Hong Tang, West China Hospital of Sichuan University

Date and Time: 8 November 2026, 5:30 pm – 5:45 pm (local time)

Venue: Late Breaking Abstract Parallel Session 2

About TQ-A3334:

TQ-A3334 is an oral, selective Toll-like receptor 7 (TLR7) agonist that reshapes the body's immune response against HBV by activating innate and adaptive immune pathways and inducing interferon and cytokine responses. It complements the direct antiviral effects of nucleos(t)ide analogues and represents a significant exploration in the field of functional cure (clinical cure) for chronic hepatitis B (CHB).

Bepirovirsen (ASO)

Two oral presentations:

Title of Abstract: Rates of functional cure in participants with chronic hepatitis B virus (HBV) infection treated with bepirovirsen: B-Well Phase 3 trials end of study results

Presenter: Man-Fung Yuen, The University of Hong Kong

Time: 7 November 2026, 11:00 am – 11:15 am (local time)

Venue: Convention Center: Bluebird Ballroom 1C

Topic: Functional Cure and Novel Therapeutics in Chronic Hepatitis B

Title of Abstract: Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12

Presenter: Pietro Lampertico, University of Milan

Time: 7 November 2026, 11:15 am – 11:30 am (local time)

Venue: Convention Center: Bluebird Ballroom 1C

Topic: Functional Cure and Novel Therapeutics in Chronic Hepatitis B

A poster of distinction:

Title of Abstract: Up to 15 Months Durability of Functional Cure in Response to Bepirovirsen Therapy in B-Well Responders Enrolled into B-Sure

Presenter: Edward Gane, University of Auckland

About Bepirovirsen:

Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO), designed to inhibit the replication of viral DNA in the body, suppress the level of hepatitis B surface antigen (HBsAg) in the blood, and stimulate the immune system to increase the chances of a durable and sustained response.

Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to address significant unmet need in hepatitis B, it was approved for marketing by Japan's Ministry of Health, Labor and Welfare (MHLW) in August 2026. It has also received Fast Track, Priority Review, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA), and has been included in the Breakthrough Therapy Designation and priority review and approval procedures by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 14 October 2026

As at the date of this announcement, the Board of the Company comprises five executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.